Stock Scorer

Bioforce Nanosciences Holdings, Inc. (BFNH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 2.5K 5K 7.5K Q1 '18: 1 Q2 '18: 5.1K Q3 '18: 5.5K Q4 '18: 5.7K Q1 '19: 5.8K Q2 '19: 6K Q3 '19: 6K Q4 '19: 0 Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Gross Profit Quarterly

0 600 1.2K 1.8K Q1 '18: 1 Q2 '18: 1.4K Q3 '18: 1.6K Q4 '18: 1.7K Q1 '19: 1.7K Q2 '19: 947 Q3 '19: 1.7K Q4 '19: 0 Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Operating Income Quarterly

-150K -100K -50K 0 50K 100K 150K Q3 '17: -2.2K Q4 '17: -24.7K Q1 '18: -24K Q2 '18: -27.5K Q3 '18: -6.6K Q4 '18: -8.6K Q1 '19: -12.9K Q2 '19: -7.2K Q3 '19: -6.3K Q4 '19: -20.2K Q2 '24: -114.4K Q3 '24: -122K Q1 '25: -133.5K Q2 '25: -122.8K Q3 '25: -115.9K Q3 '17 Q1 '18 Q3 '18 Q1 '19 Q3 '19 Q2 '24 Q1 '25 Q3 '25

Net Income Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q3 '21: -113.9K Q4 '21: -120.7K Q1 '22: -132.4K Q2 '22: -115.8K Q3 '22: -122.6K Q4 '22: -114.7K Q1 '23: -130K Q2 '23: -113.9K Q3 '23: -113.6K Q4 '23: -114.4K Q1 '24: -130.8K Q2 '24: -114.4K Q3 '24: -122K Q4 '24: -123.2K Q1 '25: -935.5K Q2 '25: -122.8K Q3 '25: -115.9K Q4 '25: -118.6K Q1 '26: -102.4K Q2 '26: 238.7K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 2K 4K 6K Q2 '18: 3.6K Q3 '18: 3.9K Q4 '18: 4.1K Q1 '19: 4.2K Q2 '19: 5K Q3 '19: 4.2K Q4 '19: 0 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Operating Cash Flow Quarterly

-45K -30K -15K 0 15K 30K 45K Q3 '21: -8.7K Q4 '21: -9K Q1 '22: -32.9K Q2 '22: -9.6K Q3 '22: -16.4K Q4 '22: -9.4K Q1 '23: -23.1K Q2 '23: -8.6K Q3 '23: -7.9K Q4 '23: -7.1K Q1 '24: -17.6K Q2 '24: -13.4K Q3 '24: -15.4K Q4 '24: -14.8K Q1 '25: -15.2K Q2 '25: -27.9K Q3 '25: -11.1K Q4 '25: -10.9K Q1 '26: 7.1K Q2 '26: -27K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '21: 0 Q2 '21: 29.3M Q3 '21: 29.3M Q1 '22: 0 Q2 '22: 29.3M Q3 '22: 29.3M Q1 '23: 29.3M Q2 '23: 29.3M Q3 '23: 29.3M Q1 '24: 29.3M Q2 '24: 29.3M Q3 '24: 29.3M Q1 '25: 32.2M Q2 '25: 33.5M Q3 '25: 33.5M Q1 '26: 33.5M Q2 '26: 33.5M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-12.00 -8.00 -4.00 0.00 4.00 8.00 12.00 Q3 '19: 0.00 Q4 '19: 0.00 Q1 '20: -10.35 Q2 '20: -10.35 Q3 '20: -10.36 Q4 '21: -0.01 Q1 '23: -0.03 Q2 '23: -0.03 Q3 '23: -0.03 Q4 '23: -0.01 Q1 '24: -0.01 Q2 '24: -0.01 Q3 '24: -0.01 Q4 '24: -0.01 Q1 '25: -0.04 Q2 '25: -0.04 Q3 '25: -0.04 Q4 '25: -0.03 Q1 '26: 0.00 Q2 '26: 0.01 Q4 '19 Q3 '20 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for BFNH: Free Cash Flow. Nothing in this filer's XBRL supports it for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.